Ultragenyx Pharmaceutical Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Ultragenyx here with us today. And we have Emil Kakkis, CEO.
Questions & Answers
With that, Emil, maybe to start, you have multiple events set to play out this year with advancement of your gene therapy portfolio in addition to commercial launches. Could you just walk us through the catalyst path for maybe the next 12 months with regard to your portfolio?
Sure, Salveen. Thanks for speaking with me today, and I'll give you kind of an update of where the catalyst [work] for the coming year. It's already June of the year, and it's been quite a year, from COVID and everything else going on in the world. There's been a lot of distractions and pain and suffering. But fortunately
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
